LEP and diabetic kidney disease: In this regard, Jenkin et al.47 reported that chronic administration of AM251 for 6 weeks with a daily dose of 3 mg/kg significantly reduced weight gain, systolic blood pressure, plasma leptin, albuminuria, plasma creatinine, and tubular cross-section diameter in a DIO model of Sprague Dawley rats, whereas Barutta et al.49 have reported that blockade of CB1 receptors ameliorates albuminuria in a diabetic nephropathy mice experimental model.